Skip to content
DeepViews
[XNAS]

Pacira BioSciences, Inc. Common Stock (PCRX)

$24.68

更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR

市值
$983.79M
企业价值
$1095.88M
市盈率
67.2
股息率
0.00%
EV/EBITDA
10.4
公司简介
关于
关于 Pacira BioSciences, Inc. Common Stock

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

行业

PHARMACEUTICAL PREPARATIONS

员工人数

829

总部

BRISBANE, CA

Exchange

XNAS

官网
Source: Polygon.io
评分
竞争壁垒
竞争壁垒
48
窄护城河

基于 4 年财务数据的系统性竞争优势评估

此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。

市场信号
估值
盈利
内部人交易
内部人备案活动

首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。

加载 SEC 内部人备案数据...
超级投资者
财务健康
财务健康

资本结构

总权益$671.98M
总债务$363.12M
债务权益比0.54
现金及等价物$205.88M

现金流

经营现金流$187.66M
自由现金流$179.51M
自由现金流率24.06%
P/FCF 比率5.48
Source: Polygon.io · SEC EDGAR
股息
最新资讯
Recent News

免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。